Oncolysin M

Drug Profile

Oncolysin M

Alternative Names: Anti-CD33-bR; Anti-My9-blocked ricin; Anti-My9-bR

Latest Information Update: 25 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer Dana-Farber Cancer Institute; ImmunoGen
  • Class Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD33 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 25 Nov 1998 Discontinued-I for Acute myeloid leukaemia in Canada (Unknown route)
  • 25 Nov 1998 Discontinued-I for Acute myeloid leukaemia in USA (Unknown route)
  • 12 Dec 1994 Phase-I clinical trials for Acute myeloid leukaemia in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top